Background The incorporation of co-stimulatory signaling domains into second-generation chimeric antigen receptors (CARs) significantly enhances the proliferation and persistence of CAR-T cells in vivo, leading to successful clinical outcomes. Methods To achieve such functional enhancement in transgenic T-cell receptor-engineered T-cell (TCR-T) therapy, we designed a second-generation TCR-T cell in which CD3 genes modified to contain… Continue reading Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus
Category: Oncology
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
Background High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy characterized by resistance to chemotherapy and high rates of recurrence. HGSC tumors display a high prevalence of tumor suppressor gene loss. Given the type 1 interferon regulatory function of BRCA1 and PTENgenes and their associated contrasting T-cell infiltrated and non-infiltrated tumor immune microenvironment… Continue reading Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer
NCI study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
According to an NCI study, patients with low-grade lymphomatoid granulomatosis who receive interferon alfa-2b, a type of immunotherapy, can live for many years after diagnosis.
NCI study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
According to an NCI study, patients with low-grade lymphomatoid granulomatosis who receive interferon alfa-2b, a type of immunotherapy, can live for many years after diagnosis.
Cancer Grand Challenges announces global research funding opportunity with nine new challenges
Nine new research challenges have been announced by NCI and Cancer Research UK as part of the Cancer Grand Challenges program to address serious issues in cancer research.
Cancer Grand Challenges announces global research funding opportunity with nine new challenges
Nine new research challenges have been announced by NCI and Cancer Research UK as part of the Cancer Grand Challenges program to address serious issues in cancer research.
NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma
The immunotherapy drug atezolizumab ( Tecentriq ) to treat advanced alveolar soft part sarcoma has received FDA approval following a clinical trial led by NCI.
NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma
The immunotherapy drug atezolizumab ( Tecentriq ) to treat advanced alveolar soft part sarcoma has received FDA approval following a clinical trial led by NCI.
Erratum to “P-309 In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in pancreatic ductal adenocarcinoma: An interim analysis”
The organizers regret that P – 309 was left out of the original ESMO 24th World Congress on Gastrointestinal Cancer 2022 Abstract Book. This abstract reads as follows:
Statement from Monica M. Bertagnolli, M.D., Director, National Cancer Institute, National Institutes of Health
a statement from the National Cancer Institute regarding NCI Director Monica M. Bertagnolli’s recent diagnosis of early breast cancer.